- In MoneyTV interview,
Warren Wang, CEO of CIIX, stated that CBD division has started selling in
China and California, planning expansion to more U.S. states and globally
to Canada and Japan
- CIIX begins
two tier referral sales program of CBD in China, offering consumers a cash
commission based on referred sales and an added incentive with company
stock
- Citing
CV Sciences, Inc. valuation, Wang projects that CIIX’s CBD subsidiary’s
market cap could reach $10-20 million; he hopes it will qualify for a
future OTC or Nasdaq listing
ChineseInvestors.com, Inc. (OTCQB: CIIX) subsidiary
ChineseHempOil.com, Inc. is planning to expand its operations to more states in
the U.S., as well as Vancouver and Toronto in Canada and Asian markets such as
Japan, CEO Warren Wang said in an interview on MoneyTV with Donald
Baillargeon (http://ibn.fm/iyH29).
It is already selling in China and Los Angeles, California.
Wang hopes that CIIX will spin off its CBD subsidiary,
ChineseHempOil.com, Inc., by year-end. “I cannot promise anything,” he noted in
the interview. “But we are looking for a listing on the OTC or a national
listing on the Nasdaq Exchange within 12 months.” CIIX’s CBD division includes
CBD Biotechnology Co. Ltd.; Hemp Logic, Inc.; and ChineseHempOil.com, Inc.,
which, combined, have already built relationships with 70 retailers in the Los
Angeles market.
For now, Wang said that CIIX is one of only three companies
selling CBD products in China. Wang added that CIIX recently ran its first
sales seminar on CBD in China from a hotel in Shanghai. The goal is to increase
and broaden the company’s consumer base, he said.
“In CBD, we are now only in Los Angeles,” Wang said of the
U.S. market. “After a month or two, we have plans to expand into Northern
California, then to New York, Texas and Colorado. We plan to reach
Chinese-Canadians in Vancouver and Toronto. We will also look in Asia, to
countries such as Japan.”
In China, it is seeking to expand its CBD cosmetic product
consumer base by utilizing a two-tiered sales system. It will offer to
customers who generate referral sales a commission based on those sales, as
well as company stock. The goal is to build ownership of CIIX among Chinese
consumers, Wang said.
Wang hopes that its CBD division will perform as well as CV
Sciences, Inc. (OTCQB: CVSI). In the interview, he projected a long term
$10-$20 million future market cap for ChineseHempOil.com, Inc., driven in part
by sales in China. After the spinoff of CBD assets, CIIX will return to its
roots in consulting, brand building and educating for the Chinese-speaking
community in the U.S. and international markets.
For more information, visit the company’s website at www.ChineseInvestors.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
